Tarsus Pharmaceuticals, Inc. (TARS) stock
Close on Oct 30, 2026Market cap $3.28BP/E –Yield 0.00%
Earnings
Tarsus Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Tarsus Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 3, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | $173.90M | +69.4% | -$0.43 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026after the close | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 23, 2026after the close | $151.67M | +128.4% | -$0.20 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025after the close | $118.70M | +146.8% | -$0.30 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025after the close | $102.66M | +151.6% | -$0.48 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 1, 2025after the close | $78.30M | +183.7% | -$0.64 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 25, 2025before the open | $66.40M | +406.9% | -$0.60 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024after the close | $48.10M | +2431.6% | -$0.61 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024after the close | $40.80M | – | -$0.88 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024after the close | $27.60M | +1004.0% | -$1.01 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024after the close | $13.10M | – | -$1.31 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023after the close | $1.90M | – | -$1.28 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023after the close | – | – | -$1.17 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023after the close | $2.50M | +400.0% | -$0.88 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 13, 2023after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022after the close | $0 | -100.0% | -$0.84 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022after the close | $15.30M | – | -$0.24 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022after the close | $500.00K | – | -$0.98 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 14, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021after the close | $1.20M | – | -$0.76 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 11, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 31, 2021after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Tarsus Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| XDEMVY net product sales | FY2026 | $685.00M – $705.00M | $670.00M – $700.00M | Raised | Aug 6, 2026 |
Guidance history
Every forecast Tarsus Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 6, 2026 | XDEMVY net product sales | FY2026 | $685.00M – $705.00M | Raised |
| May 6, 2026 | XDEMVY net product sales | FY2026 | $670.00M – $700.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Tarsus Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- News
- News
- News
- Results
- Results
- Update
- Results
- Results
- Results
- News
- News
- Results
- Update